Investor Presentation Q1 2018 Audited Results

6 Robust Financial Performance Robust financial performance with double digit top line and bottom line growth ibnsinapharma IN 1Q18 Net Revenues EGP 2.9 BN h 1Q18 Gross Profit EGP 216 MN 1Q18 EBITDA EGP 92 MN ** 1Q18 ibnsinapharma Net Profit EGP 28 MN 1Q18 Norm. Net Profit¹ EGP 36 MN ▲ 51.1% y-o-y ▲ 44.9% y-o-y ▲ 69.4% y-o-y ▲ 46.3% y-o-y ▲ 88.4% y-o-y ibnsinapharma Source: Company Management (1): Normalized net profit factors out a one-time capital increase expenses of EGP 7.5 million and a general provision of EGP 3.5 million 17

View entire presentation